BioStem Technologies (OTC: BSEM)

BioStem Technologies (OTC: BSEM) is a leading innovator in the biotechnology and pharmaceutical industries, specializing in the development, manufacture, and commercialization of allografts for regenerative therapies. The company's BioRetain processing method is at the core of its focus on manufacturing products that change lives, as it aims to maintain growth factors and preserve tissue structure. Notably, BioStem Technologies' quality management system and standard operating procedures have earned accreditation from the American Association of Tissue Banks (AATB), adhering to current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). The company's portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC, with each placental allograft processed at the company's FDA registered and AATB accredited site in Pompano Beach, Florida. The company, established in 2015, recently secured a $2.00M Post-IPO Equity investment on 03 November 2023, signaling investor confidence in BioStem Technologies' trajectory. The absence of information regarding specific investors that participated in this latest funding round suggests an opportunity for further exploration of the company's investor base. As the company continues to pioneer advancements in regenerative medicine, its continued access to financial resources and strategic partnerships will be crucial in driving its mission of harnessing perinatal tissue's natural properties to develop transformative regenerative therapies.